Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinicomolecular predictor
Purpose: This study aimed to evaluate a modified EPclin test (mEPclin), a combination of EndoPredict (EP) score, post-neoadjuvant pathologic tumor size and nodal status, for predicting the risk of distance recurrence after neoadjuvant chemotherapy (NACT) in patients with residual estrogen receptor (...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
April 4, 2018
|
| In: |
Clinical cancer research
Year: 2018, Jahrgang: 24, Heft: 14, Pages: 3358-3365 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-17-2947 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1158/1078-0432.CCR-17-2947 Verlag: https://clincancerres.aacrjournals.org/content/24/14/3358 
|
| Verfasserangaben: | Sibylle Loibl, Karsten Weber, Jens Huober, Kristin Krappmann, Frederik Marmé, Christian Schem, Knut Engels, Berit Maria Pfitzner, Sherko Kümmel, Jenny Furlanetto, Arndt Hartmann, Silvia Darb-Esfahani, Volkmar Müller, Annette Staebler, Gunter von Minckwitz, Ralf Kronenwett, and Carsten Denkert |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1691159611 | ||
| 003 | DE-627 | ||
| 005 | 20230428055008.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200227s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-17-2947 |2 doi | |
| 035 | |a (DE-627)1691159611 | ||
| 035 | |a (DE-599)KXP1691159611 | ||
| 035 | |a (OCoLC)1341308352 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Loibl, Sibylle |e VerfasserIn |0 (DE-588)12433024X |0 (DE-627)085790508 |0 (DE-576)294122753 |4 aut | |
| 245 | 1 | 0 | |a Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinicomolecular predictor |c Sibylle Loibl, Karsten Weber, Jens Huober, Kristin Krappmann, Frederik Marmé, Christian Schem, Knut Engels, Berit Maria Pfitzner, Sherko Kümmel, Jenny Furlanetto, Arndt Hartmann, Silvia Darb-Esfahani, Volkmar Müller, Annette Staebler, Gunter von Minckwitz, Ralf Kronenwett, and Carsten Denkert |
| 264 | 1 | |c April 4, 2018 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.02.2020 | ||
| 520 | |a Purpose: This study aimed to evaluate a modified EPclin test (mEPclin), a combination of EndoPredict (EP) score, post-neoadjuvant pathologic tumor size and nodal status, for predicting the risk of distance recurrence after neoadjuvant chemotherapy (NACT) in patients with residual estrogen receptor (ER)-positive/HER2-negative breast cancer. We also compared the prognostic power of the mEPclin with that of the CPS-EG score. - Experimental Design: A total of 428 formalin-fixed, paraffin-embedded tumor samples from GeparTrio and GeparQuattro studies were evaluated for mRNA expression of eight cancer-related and three reference genes. The mEPclin score was computed using a modified algorithm and predefined cut-off values were used to classify each patient at low or high risk. Primary endpoint was disease-free survival (DFS). - Results: A higher continuous mEPclin score was significantly associated with increased risk of relapse [HR, 2.16; 95% confidence interval (CI), 1.86-2.51; P < 0.001] and death (HR, 2.28; 95% CI, 1.90-2.75; P < 0.001). Similarly, patients classified at high risk by dichotomous mEPclin showed significantly poorer DFS and overall survival compared with those at low risk. In contrast with CPS-EG, the mEPclin remained significantly prognostic for DFS in multivariate analysis (HR, 2.13; 95% CI, 1.73-2.63; P < 0.001). Combining CPS-EG and other clinicopathological variables with mEPclin yielded a significant improvement of the prognostic power for DFS versus without mEPclin (c-indices: 0.748 vs. 0.660; P < 0.001). - Conclusions: The mEPclin score independently predicted the risk of distance recurrence and provided additional prognostic information to the CPS-EG score to assess more accurately the prognosis after NACT in the luminal non-pCR patient population. Therefore, this approach can be used to select patients for additional post-neoadjuvant therapies. Clin Cancer Res; 24(14); 3358-65. ©2018 AACR. | ||
| 700 | 1 | |a Weber, Karsten |e VerfasserIn |4 aut | |
| 700 | 1 | |a Huober, Jens |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krappmann, Kristin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 700 | 1 | |a Schem, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Engels, Knut |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pfitzner, Berit Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kümmel, Sherko |e VerfasserIn |4 aut | |
| 700 | 1 | |a Furlanetto, Jenny |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hartmann, Arndt |e VerfasserIn |4 aut | |
| 700 | 1 | |a Darb-Esfahani, Silvia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Müller, Volkmar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Staebler, Annette |e VerfasserIn |4 aut | |
| 700 | 1 | |a Minckwitz, Gunter von |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kronenwett, Ralf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Denkert, Carsten |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 24(2018), 14, Seite 3358-3365 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinicomolecular predictor |
| 773 | 1 | 8 | |g volume:24 |g year:2018 |g number:14 |g pages:3358-3365 |g extent:8 |a Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinicomolecular predictor |
| 856 | 4 | 0 | |u https://doi.org/10.1158/1078-0432.CCR-17-2947 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://clincancerres.aacrjournals.org/content/24/14/3358 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20200227 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 910000 |d 910400 |e 910000PM132561972 |e 910400PM132561972 |k 0/910000/ |k 1/910000/910400/ |p 5 | ||
| 999 | |a KXP-PPN1691159611 |e 3598937113 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1691159611","id":{"eki":["1691159611"],"doi":["10.1158/1078-0432.CCR-17-2947"]},"name":{"displayForm":["Sibylle Loibl, Karsten Weber, Jens Huober, Kristin Krappmann, Frederik Marmé, Christian Schem, Knut Engels, Berit Maria Pfitzner, Sherko Kümmel, Jenny Furlanetto, Arndt Hartmann, Silvia Darb-Esfahani, Volkmar Müller, Annette Staebler, Gunter von Minckwitz, Ralf Kronenwett, and Carsten Denkert"]},"relHost":[{"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"pubHistory":["1.1995 -"],"title":[{"title_sort":"Clinical cancer research","title":"Clinical cancer research"}],"origin":[{"dateIssuedDisp":"1995-","publisherPlace":"Philadelphia, Pa. [u.a.]","publisher":"AACR","dateIssuedKey":"1995"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"corporate":[{"role":"isb","display":"American Association for Cancer Research"}],"part":{"text":"24(2018), 14, Seite 3358-3365","year":"2018","issue":"14","extent":"8","volume":"24","pages":"3358-3365"},"disp":"Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinicomolecular predictorClinical cancer research","physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"id":{"eki":["325489971"],"zdb":["2036787-9"],"issn":["1557-3265"]},"recId":"325489971","name":{"displayForm":["American Association for Cancer Research"]}}],"physDesc":[{"extent":"8 S."}],"language":["eng"],"person":[{"family":"Loibl","given":"Sibylle","display":"Loibl, Sibylle","role":"aut"},{"role":"aut","display":"Weber, Karsten","given":"Karsten","family":"Weber"},{"role":"aut","display":"Huober, Jens","family":"Huober","given":"Jens"},{"role":"aut","display":"Krappmann, Kristin","family":"Krappmann","given":"Kristin"},{"role":"aut","family":"Marmé","given":"Frederik","display":"Marmé, Frederik"},{"family":"Schem","given":"Christian","display":"Schem, Christian","role":"aut"},{"role":"aut","display":"Engels, Knut","family":"Engels","given":"Knut"},{"display":"Pfitzner, Berit Maria","family":"Pfitzner","given":"Berit Maria","role":"aut"},{"role":"aut","family":"Kümmel","given":"Sherko","display":"Kümmel, Sherko"},{"display":"Furlanetto, Jenny","family":"Furlanetto","given":"Jenny","role":"aut"},{"role":"aut","display":"Hartmann, Arndt","given":"Arndt","family":"Hartmann"},{"role":"aut","display":"Darb-Esfahani, Silvia","family":"Darb-Esfahani","given":"Silvia"},{"display":"Müller, Volkmar","given":"Volkmar","family":"Müller","role":"aut"},{"display":"Staebler, Annette","given":"Annette","family":"Staebler","role":"aut"},{"role":"aut","family":"Minckwitz","given":"Gunter von","display":"Minckwitz, Gunter von"},{"family":"Kronenwett","given":"Ralf","display":"Kronenwett, Ralf","role":"aut"},{"family":"Denkert","given":"Carsten","display":"Denkert, Carsten","role":"aut"}],"title":[{"title":"Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinicomolecular predictor","title_sort":"Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinicomolecular predictor"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"April 4, 2018","dateIssuedKey":"2018"}],"note":["Gesehen am 27.02.2020"]} | ||
| SRT | |a LOIBLSIBYLRISKASSESS4201 | ||